Navigation Links
Replidyne and Cardiovascular Systems Sign Merger Agreement
Date:11/4/2008

m" target="_new">http://www.csi360.com.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne and CSI that involve significant risks and uncertainties. Examples of such statements include, but are not limited to, the anticipated closing date of the merger, the expected cash that will be available to CSI at the closing of the merger, the expected ownership of the stockholders of Replidyne and CSI after the closing of the merger, and the anticipated benefits of the transaction. Actual results could differ materially from those discussed in the forward looking statements due to a number of factors including, the outcome of the shareholder vote for the proposed merger, the outcome of Replidyne's efforts to wind up its business including the disposition of its research pipeline programs; regulatory developments in the U.S. and foreign countries; the accuracy of Replidyne's or CSI's estimates regarding expenses, future revenues and capital requirements; and CSI's ability to obtain and maintain intellectual property protection for product candidates. These and additional risks and uncertainties are described more fully in CSI's registration statement on Form 10 filed with the Securities and Exchange Commission (SEC) on October 28, 2008 and Replidyne's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis and retrieval system (EDGAR) at http://www.sec.gov. All forward-looking statements made in the press release are made as of the date hereof and neither Replidyne nor CSI assumes any obligation to update the forward-looking statements in the document.

Additional information about the Merger and Where to Find It

This communication may be deemed to be solicitation ma
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Replidyne Announces Second Quarter 2008 Results From Operations
2. Replidyne Terminates Faropenem Agreements
3. Replidyne to Report First Quarter 2008 Earnings
4. Replidyne Announces 2007 Fourth Quarter and Full Year Results
5. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
6. Replidyne to Announce Third Quarter 2007 Earnings
7. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
8. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
9. CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
10. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
11. Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During Live Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ISTANBUL , May 21, 2013 ...  European Dialysis and Transplant Association) is the biggest congress ... renal replacement therapy. Nearly 10,000 participants are in ... discuss the latest research findings. New pioneering studies have ... al. "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ...
(Date:5/21/2013)... 21, 2013 According to a ... http://www.transparencymarketresearch.com ) "Biochip Products and Services Market (Microarrays, Reagents, ... Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market ... is expected to grow at a CAGR of 10.1% ... of USD 4.7 billion in 2018. Browse ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Revolutionary Science, ... automatic colony counter, announced today that they have expanded ... products , the IncuCount, IntelliCount, InCount and ImpressCount. ... sophistication are especially useful in food microbiology and pharmaceutical ... an updated look. A bright white enclosure with ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2
... Inc. (Nasdaq:,EVVV) will release its 2008 second quarter and ... market trading hours., The company will host a ... Central Time (8:30 a.m. Eastern Time). ev3 management will ... by a,question and answer session., The conference call ...
... an Attractive Domestic Alternative to High Priced ... Fulcrum BioEnergy, Inc.,today announced that it is ... build one of the first commercial-scale production,facilities ... The plant will,process municipal solid waste-household garbage ...
... environmental technology,company SEKAB has signed an agreement for ... LDC Bioenergia, a Brazilian ethanol,and sugar industry leader ... "The agreement safeguards supplies of additional volumes ... environmental and social,sustainability," says Anders Fredriksson, Executive Vice ...
Cached Biology Technology:ev3 Inc. to Report 2008 Second Quarter Financial Results and Host Conference Call on August 1, 2008 2Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 2Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 3SEKAB Agreement: More Verified Ethanol to Europe 2
(Date:5/20/2013)... Foundation (NSF) planning grant will help establish the Center ... of the University of Illinois at Urbana-Champaign and Worcester ... be devoted to research in drying moist, porous materials ... paper products; chemical products; textiles; and biopharmaceuticals," said Hao ... and human nutrition and the Illinois site director. , ...
(Date:5/20/2013)... at the University of Bristol and published online today ... light on how the brain and inner ear developed ... of Earth Sciences, together with Tom Hbner from the ... 150 million year old dinosaurs. , The two palaeontologists ... lettowvorbecki : a very young (juvenile) individual of ...
(Date:5/19/2013)... reports that white men and women of European descent ... and lesser toe deformities, including hammer or claw toe. ... the heritability of foot disorders in humansappear in ... Wiley on behalf of the American College of Rheumatology ... as 60% of older adults have foot disorders which ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Fossil brain teaser 2Blame your parents for bunion woes 2
... more common in areas of mountaintop coal mining and ... common, according to a study by researchers at Washington ... led by Melissa Ahern, health economist and associate professor ... per 10,000 births where mountaintop mining is most common ...
... 23, 2011 (Bethesda, MD): Today, on behalf of the ... public comments at the US Food and Drug Administration,s ... Diagnostic Applications Approaches to Assess Analytical Validity." As ... diagnostics, AMP advised FDA officials on many important considerations ...
... will promote fish stock recovery and increase fishermen,s incomes, according ... In the North Sea up to 75 per cent of ... that many fisheries are now badly overfished. In comparison, discards ... their fisheries are now some of the most prosperous in ...
Cached Biology News:Large numbers of birth defects seen near mountaintop mining operations 2AMP comments at FDA meeting on next-generation sequencing 2Discards ban 'will boost fisheries', says new research 2
sodium channel, nonvoltage-gated 1 alpha,...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 9 ... tubes. Box dimensions: 13 x 13 x ...
Biology Products: